Margaret R MacLean
Overview
Explore the profile of Margaret R MacLean including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
3194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Montezano A, Kuriakose J, Hood K, Sin Y, Camargo L, Namkung Y, et al.
Hypertension
. 2024 Dec;
82(2):267-281.
PMID: 39633565
Background: Ang-(1-7) (angiotensin (1-7)) via MasR (Mas receptor) opposes vaso-injurious actions of Ang II (angiotensin II) as shown in models of pulmonary hypertension. The underlying mechanisms remain unclear. We hypothesized...
2.
McCarthy B, Feng R, Torigian D, Tong Y, Fritz J, Minhas J, et al.
Chest
. 2024 Nov;
PMID: 39613149
Background: Increased epicardial adipose tissue (EAT) has adverse effects in cardiovascular diseases, independent of BMI. Estrogen levels may affect EAT accumulation. Little is known about the predictors and potential impact...
3.
Dignam J, Sharma S, Stasinopoulos I, MacLean M
Br J Pharmacol
. 2023 Nov;
181(7):938-966.
PMID: 37939796
Pulmonary arterial hypertension (PAH) is a complex disease of multifactorial origin. While registries have demonstrated that women are more susceptible to the disease, females with PAH have superior right ventricle...
4.
Morris H, Neves K, Nilsen M, Montezano A, MacLean M, Touyz R
Hypertension
. 2023 May;
80(8):1683-1696.
PMID: 37254738
Background: Notch3 (neurogenic locus notch homolog protein 3) is implicated in vascular diseases, including pulmonary hypertension (PH)/pulmonary arterial hypertension. However, molecular mechanisms remain elusive. We hypothesized increased Notch3 activation induces...
5.
MacLean M, Pandya D, Swietlik E, Denver N, Mair K, Morrell N, et al.
Pulm Circ
. 2022 Oct;
12(3):e12139.
PMID: 36186719
The hypothesis that a relationship exists between body mass index (BMI), functional class, and 6 min walk distance (6MWD) in Group 1-pulmonary arterial hypertension (PAH) was examined. Analysis of data...
6.
MacLean M, Fanburg B, Hill N, Lazarus H, Pack T, Palacios M, et al.
Compr Physiol
. 2022 Aug;
12(4):4103-4118.
PMID: 36036567
Serotonin is often referred to as a "happy hormone" as it maintains good mood, well-being, and happiness. It is involved in communication between nerve cells and plays a role in...
7.
Labazi H, Nilsen M, MacLean M
Eur J Pharmacol
. 2021 Mar;
900:174066.
PMID: 33789156
Methamphetamine (MA) abuse is associated with the development of pulmonary arterial hypertension (PAH) and subsequent right ventricular failure. A recent clinical study demonstrated that female sex is a major risk...
8.
Morris H, Denver N, Gaw R, Labazi H, Mair K, MacLean M
Clin Chest Med
. 2021 Feb;
42(1):217-228.
PMID: 33541615
Pulmonary arterial hypertension (PAH) occurs in women more than men whereas survival in men is worse than in women. In recent years, much research has been carried out to understand...
9.
Docherty C, Denver N, Fisher S, Nilsen M, Hillyard D, Openshaw R, et al.
Mol Ther Nucleic Acids
. 2020 Nov;
22:396-405.
PMID: 33230444
The 5HT1B receptor (5HT1BR) contributes to the pathogenic effects of serotonin in pulmonary arterial hypertension. Here, we determine the effect of a microRNA96 (miR96) mimic delivered directly to the lungs...
10.
Labazi H, Axelsen J, Hillyard D, Nilsen M, Andersen A, MacLean M
Biomedicines
. 2020 Oct;
8(10).
PMID: 33086482
Right ventricular hypertrophy (RVH) and subsequent failure are consequences of pulmonary arterial hypertension (PAH). While females are four times more likely to develop PAH, male patients have poorer survival even...